Evidence map›Paper›PMID 19169153›Full record

ReviewThe Journal of craniofacial surgery2009

Progenitor cells in infantile hemangioma.

Joyce Bischoff

Erratum issuedAbstract readReview
In one paragraph

Review in The Journal of craniofacial surgery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Biological identity of orbital cavernous venous malformations.Arquivos brasileiros de oftalmologia · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Endothelial CaInternational journal of molecular sciences · 2018
    Review
  9. Article
  10. Observational
  11. Review
  12. Complex vascular anomalies.Pediatric surgery international · 2013
    Review
  13. Pathogenesis of vascular anomalies.Clinics in plastic surgery · 2011
    Review
  14. Article
  15. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

1 author.

Joyce BischoffDepartment of Surgery, Vascular Biology Program, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. joyce.bischoff@childrens.harvard.edu

Funding

Pathogenic mechanisms of venous anomaliesP01AR048564 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI OLSEN, BJORN REINO · 2003 to 2013
$13.4M
Blood vessel assembly from multipotent hemangioma-derived stem cellsR01HL096384 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Joyce E. Bischoff · 2009 to 2026
$7.7M
NHLBI NIH HHS R01 HL096384NIAMS NIH HHS P01 AR048564NIAMS NIH HHS P01 AR48564
6 · The paper itself

Abstract

Infantile hemangioma is a vascular tumor that occurs in 5% to 10% of infants of European descent. A hallmark of infantile hemangioma is its life cycle, which is divided into 3 stages. The proliferating phase spans in the first year of postnatal life and is characterized by cellular masses without a defined vascular architecture and nascent blood vessels with red blood cells evident within the lumenal space. The involuting phase begins at 1 year of age and continues for 3 to 5 years. Proliferation slows or stops in this phase, and histologic examination shows that the blood vessel architecture becomes more obvious and vessel size is enlarged. The involuted phase reaches 5 to 8 years of age, at which point blood vessels are replaced with a fibrofatty residuum and capillary-sized channels. The growth and involution life cycle of infantile hemangioma are very different from other vascular tumors and vascular malformations, which do not regress and can occur at any time during childhood or adult life. Many laboratories have reported on the endothelial characteristics of the cellular masses that are prominent in the proliferating phase of infantile hemangioma, as well as their immature appearance. These studies, along with isolation and characterization of hemangioma-derived cell populations with progenitor cell properties, have lead to an emerging hypothesis that hemangioma is caused by an abnormal or delayed differentiation of mesodermal progenitor cells into the disorganized mass of blood vessels. In this paper, we discuss the literature that supports this emerging hypothesis.

Indexed as

Cell LineageChildChild, PreschoolHead and Neck NeoplasmsHemangiomaHumansInfantInfant, NewbornMesenchymal Stem CellsMultipotent Stem CellsNeoplasm Regression, SpontaneousNeoplastic Stem CellsNeovascularization, Pathologic

Identifiers

PMID19169153
PMCPMC2810465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.